Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Cartesian Therapeutics (RNAC) Return on Sales (2016 - 2025)

Cartesian Therapeutics (RNAC) has disclosed Return on Sales for 11 consecutive years, with 342.06% as the latest value for Q4 2025.

  • On a quarterly basis, Return on Sales fell 37110.0% to 342.06% in Q4 2025 year-over-year; TTM through Dec 2025 was 342.06%, a 34112.0% decrease, with the full-year FY2025 number at 325.74%, down 32371.0% from a year prior.
  • Return on Sales was 342.06% for Q4 2025 at Cartesian Therapeutics, down from 65.5% in the prior quarter.
  • In the past five years, Return on Sales ranged from a high of 65.5% in Q3 2025 to a low of 342.06% in Q4 2025.
  • A 5-year average of 20.87% and a median of 0.72% in 2021 define the central range for Return on Sales.
  • Biggest YoY gain for Return on Sales was 10426bps in 2025; the steepest drop was -37110bps in 2025.
  • Cartesian Therapeutics' Return on Sales stood at 0.41% in 2021, then decreased by -15bps to 0.35% in 2022, then plummeted by -1320bps to 4.28% in 2023, then skyrocketed by 778bps to 29.04% in 2024, then tumbled by -1278bps to 342.06% in 2025.
  • Per Business Quant, the three most recent readings for RNAC's Return on Sales are 342.06% (Q4 2025), 65.5% (Q3 2025), and 67.33% (Q2 2025).